1 week Ago By ABMN Staff
Norges Bank bought a new position in shares of Travere Therapeutics, Inc. ( NASDAQ:TVTX – Free Report ) in the 4th quarter, Holdings Channel.com reports.
The institutional investor bought 71,000 shares of the company’s stock, valued at approximately $1,237,000. Several other institutional investors and hedge funds also recently made changes to their positions in TVTX. R Squared Ltd bought a new stake in Travere Therapeutics during the 4th quarter worth approximately $53,000.
Victory Capital Management Inc. acquired a new stake in Travere Therapeutics during the 4th quarter worth $182,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Travere Therapeutics during the 4th quarter valued at $192,000.
Entropy Technologies LP acquired a new position in Travere Therapeutics in the fourth quarter valued at about $214,000. Finally, E Fund Management Co. Ltd.
acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $217,000. Analyst Upgrades and Downgrades Several brokerages have recently issued reports on TVTX. JPMorgan Chase & Co.
boosted their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th.
Scotiabank lifted their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th.
Cantor Fitzgerald reissued an “overweight” rating on shares of Travere Therapeutics in a research note on Thursday, April 3rd. Canaccord Genuity Group lifted their price target on shares of Travere Therapeutics from $45.00 to $47.
00 and gave the company a “buy” rating in a research note on Thursday. Finally, Bank of America increased their price objective on shares of Travere Therapeutics from $29.00 to $31.
00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.
62. Travere Therapeutics Price Performance NASDAQ:TVTX opened at $14.50 on Friday.
Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $25.
29. The company has a market cap of $1.29 billion, a P/E ratio of -3.
54 and a beta of 0.84. The company has a debt-to-equity ratio of 24.
96, a quick ratio of 1.68 and a current ratio of 1.71.
The stock’s 50-day simple moving average is $19.60 and its 200 day simple moving average is $18.57.
Travere Therapeutics ( NASDAQ:TVTX – Get Free Report ) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.
58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.
87% and a negative net margin of 137.90%. The company had revenue of $74.
79 million for the quarter, compared to the consensus estimate of $72.38 million. As a group, sell-side analysts forecast that Travere Therapeutics, Inc.
will post -1.4 EPS for the current fiscal year. Insider Buying and Selling at Travere Therapeutics In other news, CFO Christopher R.
Cline sold 5,192 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $20.12, for a total value of $104,463.
04. Following the completion of the sale, the chief financial officer now directly owns 90,038 shares of the company’s stock, valued at $1,811,564.56.
This trade represents a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link .
Also, CAO Sandra Calvin sold 54,244 shares of Travere Therapeutics stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.
00. Following the transaction, the chief accounting officer now owns 54,410 shares of the company’s stock, valued at $1,360,250. This represents a 49.
92 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 188,829 shares of company stock worth $4,146,997 over the last quarter.
4.06% of the stock is currently owned by insiders. About Travere Therapeutics ( Free Report ) Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Read More Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc.
( NASDAQ:TVTX – Free Report ). Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
